


DAVID T. WONG

# Salivary Diagnostics



 WILEY-BLACKWELL

# **Salivary Diagnostics**



# Salivary Diagnostics

Edited by  
David T. Wong  
DMD, DMSc

 **WILEY-BLACKWELL**

A John Wiley & Sons, Ltd., Publication

Edition first published 2008  
© 2008 Wiley-Blackwell  
Chapters 1, 8, 10, and 27 are with the U.S. Government

Blackwell Munksgaard, formerly an imprint of Blackwell Publishing was acquired by John Wiley & Sons in February 2007. Blackwell's publishing program has been merged with Wiley's global Scientific, Technical, and Medical business to form Wiley-Blackwell.

*Editorial Office*  
2121 State Avenue, Ames, Iowa 50014-8300, USA

For details of our global editorial offices, for customer services and for information about how to apply for permission to reuse the copyright material in this book please see our website at [www.wiley.com/wiley-blackwell](http://www.wiley.com/wiley-blackwell).

Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by the publisher, provided that the base fee is paid directly to the Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923. For those organizations that have been granted a photocopy license by CCC, a separate system of payments has been arranged. The fee codes for users of the Transactional Reporting Service are ISBN-13: 978-0-8138-1333-2/2008.

Designations used by companies to distinguish their products are often claimed as trademarks. All brand names and product names used in this book are trade names, service marks, trademarks or registered trademarks of their respective owners. The publisher is not associated with any product or vendor mentioned in this book. This publication is designed to provide accurate and authoritative information in regard to the subject matter covered. It is sold on the understanding that the publisher is not engaged in rendering professional services. If professional advice or other expert assistance is required, the services of a competent professional should be sought.

Disclaimer: The contents of this work are intended to further general scientific research, understanding, and discussion only and are not intended and should not be relied upon as recommending or promoting a specific method, diagnosis, or treatment by practitioners for any particular patient. The publisher and the author make no representations or warranties with respect to the accuracy or completeness of the contents of this work and specifically disclaim all warranties, including without limitation any implied warranties of fitness for a particular purpose. In view of ongoing research, equipment modifications, changes in governmental regulations, and the constant flow of information relating to the use of medicines, equipment, and devices, the reader is urged to review and evaluate the information provided in the package insert or instructions for each medicine, equipment, or device for, among other things, any changes in the instructions or indication of usage and for added warnings and precautions. Readers should consult with a specialist where appropriate. The fact that an organization or Website is referred to in this work as a citation and/or a potential source of further information does not mean that the author or the publisher endorses the information the organization or Website may provide or recommendations it may make. Further, readers should be aware that Internet Websites listed in this work may have changed or disappeared between when this work was written and when it is read. No warranty may be created or extended by any promotional statements for this work. Neither the publisher nor the author shall be liable for any damages arising herefrom.

Library of Congress Cataloging-in-Publication Data

Salivary diagnostics / edited by David T. Wong.  
p. ; cm.

Includes bibliographical references and index.

ISBN 978-0-8138-1333-2 (alk. paper)

1. Saliva—Examination. 2. Mouth—Diseases—Diagnosis. I. Wong, David, 1954—

[DNLM: 1. Saliva—physiology. 2. Biological Markers. 3. Communicable Diseases—diagnosis.

4. Mouth Diseases—diagnosis. QY 125 S1678 2008]

RB52.5.S25 2008

616.3'16075—dc22

2008025004

A catalogue record for this book is available from the U.S. Library of Congress.

Set in 10/12pt Palatino by Aptara® Inc., New Delhi, India  
Printed in Singapore by Fabulous Printers Pte Ltd

# Contents

	Contributors	viii
	Foreword	xv
	Preface	xvii
	Acknowledgment	xviii
<b>I</b>	<b>Background and Foundation</b>	
1	Salivary Gland Development and Regeneration <i>Sarah M. Knox and Matthew P. Hoffman</i>	3
2	Salivary Gland Physiology Relevant to Diagnostics <i>Victor G. Romanenko and James E. Melvin</i>	14
3	Saliva: Properties and Functions <i>Arie van Nieuw Amerongen, Enno C.I. Veerman, and Arjan Vissink</i>	27
4	Saliva Collectors <i>Arjan Vissink, Andy Wolff, and Enno C.I. Veerman</i>	37
5	Salivary Secretion in Health and Disease <i>Michael D. Turner and Jonathan A. Ship</i>	60
6	Processing and Storage of Saliva Samples <i>Enno C.I. Veerman, Arjan Vissink, David T. Wong, and Arie van Nieuw Amerongen</i>	69

**II Saliva Diagnostics**

7	Historical Perspectives and Present <i>Frank G. Oppenheim</i>	79
8	Diagnostics Other Than Blood <i>Sudhir Srivastava and Karl Krueger</i>	94
9	Perceptions of Saliva: Relevance to Clinical Diagnostics <i>Sreenivas Koka and David T. Wong</i>	104
10	Saliva-Based Diagnostic Technologies: Highlights of the NIDCR's Program <i>Eleni Kousvelari, John T. McDevitt, Daniel Malamud, David T. Wong, and David R. Walt</i>	111
11	Human Salivary Proteomics <i>Shen Hu, Markus Hardt, Susan J. Fisher, David T. Wong, John R. Yates, James E. Melvin, and Joseph A. Loo</i>	122
12	Genomic Targets in Saliva <i>Bernhard G. Zimmermann, Zhanzhi Hu, and David T. Wong</i>	129
13	Point-of-Care Diagnostics for Infectious diseases <i>Paul L.A.M. Corstjens, Daniel Malamud</i>	136
14	Dental Caries Risk Assessment <i>Paul C. Denny and Patricia A. Denny</i>	150
15	Periodontal Disease <i>Christoph A. Ramseier, Thiago Morelli, Janet S. Kinney, Meghan Dubois, Lindsay Rayburn, and William Giannobile</i>	156
16	Role of Saliva in Detection of Substance Abuse <i>Uttam Garg and Lance Presley</i>	169
17	Head and Neck Cancer <i>Joseph A. Califano and Suhail K. Mithani</i>	180
18	Sjögren's Syndrome <i>Philip C. Fox</i>	189
19	Salivary Gland Dysfunction Associated with Systemic Disease <i>Nelson L. Rhodus</i>	198

---

20	Progression and Treatment Evaluation in Diseases Affecting Salivary Glands	214
	<i>Jiska M. Meijer, Cees G.M. Kallenberg, and Arjan Vissink</i>	
21	The Uses of Saliva in Forensic Genetics	226
	<i>Jack Ballantyne and Jane Juusola</i>	
22	SPKB—Salivary Proteome Knowledge Base: A Platform for Collaborative Proteomics Research	233
	<i>Weihong Yan, Weixia Yu, Shawn Than, Renli Qiao, D. Stott Parker, Joseph A. Loo, and David T. Wong</i>	
<b>III</b>	<b>Saliva Diagnostics—A New Industry</b>	
23	Commercialization of Oral Fluid Products and Technologies	243
	<i>R. Sam Niedbala</i>	
24	Coverage and Reimbursement for Salivary Diagnostic Tests	255
	<i>James J. Crall</i>	
25	Saliva Diagnostics in the Dentist’s and Physician’s Office	263
	<i>Chakwan Siew and Milton V. Marshall</i>	
26	Salivary Hormones in Research and Diagnostics	270
	<i>Douglas A. Granger, Christine K. Fortunato, Leah C. Hibel</i>	
27	Crossroads Between Saliva Diagnostics and Salivary Gland Gene Therapy	278
	<i>Bruce J. Baum, Ana P. Cotrim, Corinne M. Goldsmith, Fumi Mineshiba, Senrong Qi, Gabor Z. Racz, Yuval Samuni, Takayuki Sugito, Antonis Voutetakis, and Changyu Zheng</i>	
28	Saliva Diagnostics—A New Industry	288
	<i>Stuart R. Smith, David T. Wong, and R. Michael Buch</i>	
	Index	295



# Contributors

**Arie van Nieuw Amerongen, PhD**

Professor, Department of Oral Biochemistry, ACTA, Medical Faculty,  
Vrije Universiteit, Van der Boechorststraat 7, 1081 BT Amsterdam,  
the Netherlands

**Jack Ballantyne, PhD**

University of Central Florida, 4000 Central Florida, Orlando, FL 32816

**Bruce J. Baum, DMD, PhD**

National Institute of Dental and Craniofacial Research, 9402 Balfour Drive,  
Bethesda, MD 20814

**R. Michael Buch, PhD**

GlaxoSmithKline (GSK), Parsippany, NJ 07054

**Joseph A. Califano, MD**

Professor, Johns Hopkins Medical Center, Baltimore, MD 21287

**Paul L.A.M. Corstjens, PhD**

Assistant Professor, Department of Molecular Cell Biology, Leiden University  
Medical Center, 2300 RC Leiden, the Netherlands

**Ana P. Cotrim, DDS, PhD**

Gene Transfer Section, Gene Therapy and Therapeutics Branch, National  
Institute of Dental and Craniofacial Research, National Institutes of Health,  
Department of Health and Human Services, Bethesda, MD 20892

**James J. Crall, DDS, ScD**

Professor and Chair, Section of Pediatric Dentistry Director, MCHB National  
Oral Health Policy Center, UCLA School of Dentistry, CHS 23-020A,  
10833 Le Conte Avenue, Los Angeles, CA 90095

**Paul C. Denny, PhD**

Professor, Division of Diagnostic Sciences, School of Dentistry, University of Southern California, Los Angeles, CA 90089

**Patricia A. Denny, MA**

Division of Diagnostic Sciences, School of Dentistry, University of Southern California, Los Angeles, CA 90089

**Meghan Dubois, BS**

Research Fellow, Michigan Center for Oral Health Research, University of Michigan Clinical Center, 24 Frank Lloyd Wright Dr, Lobby M, Box 422, Ann Arbor, MI 48106

**Susan J. Fisher, PhD**

Department of Cell and Tissue Biology, University of California at San Francisco, 513 Parnassus Avenue, San Francisco, CA 94143

**Christine K. Fortunato, BS**

Department of Human Development and Family Studies, Pennsylvania State University, University Park, PA 16803

**Philip C. Fox, DDS**

Visiting Scientist, Department of Oral Medicine, Carolinas Medical Center, Charlotte, NC, and, President, PC Fox Consulting, LLC Via Monterione, 29, 06038 Spello (PG), Italy

**Uttam Garg, PhD**

Professor, University of Missouri Kansas City School of Medicine, Director, Clinical Chemistry and Toxicology Laboratories, Department of Pathology and Laboratory Medicine, Children's Mercy Hospitals and Clinics, Kansas City, MO 64108

**William V. Giannobile, DDS, DMedSc**

Najjar Professor of Dentistry and Director, Michigan Center for Oral Health Research, University of Michigan Clinical Center, Professor of Biomedical Engineering, 24 Frank Lloyd Wright Dr, Lobby M, Box 422, Ann Arbor, MI 48106

**Corinne M. Goldsmith, BS**

Gene Transfer Section, Gene Therapy and Therapeutics Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892

**Douglas A. Granger, PhD**

Pennsylvania State University, University Park, PA 16802

**Markus Hardt, PhD**

Department of Cell and Tissue Biology, University of California at San Francisco, 513 Parnassus Avenue, San Francisco, CA 94143

**Leah C. Hibel, BS**

Department of Biobehavioral Health, Pennsylvania State University,  
University Park, PA 16802

**Matthew P. Hoffman, BDS, PhD**

Matrix and Morphogenesis Unit, CDBRB, National Institutes of  
Health/NIDCR, 30 Convent Dr MSC 4370, Bethesda, MD 20892

**Shen Hu, PhD**

Associate Professor, Division of Oral Biology, UCLA School of Dentistry,  
10833 Le Conte Avenue, Los Angeles, CA 90095

**Zhanzhi Hu, PhD**

Postdoctoral Research Fellow, Division of Oral Biology, UCLA School of  
Dentistry, Los Angeles, CA

**Jane Juusola, PhD**

Educational Programs Coordinator, Molecular Diagnostics Laboratory,  
Department of Pathology, Virginia Commonwealth University Medical  
Center, Richmond, VA 23298

**Cees G.M. Kallenberg, MD**

University Medical Center Groningen, Hanzplein 1, PO Box 30 001, 9700 RB,  
Groninger, the Netherlands

**Janet S. Kinney, RDH, MS**

Assistant Professor, Michigan Center for Oral Health Research, University of  
Michigan Clinical Center, 24 Frank Lloyd Wright Dr, Lobby M, Box 422, Ann  
Arbor, MI 48106

**Sarah M. Knox, PhD**

Visiting Fellow, Matrix and Morphogenesis Unit, LCDB, NIDCR, NIH, 30  
Convent Dr, Bethesda, MD 20892

**Sreenivas Koka, DDS, MS, PhD**

Professor, Mayo Clinic School of Medicine, Rochester, MN 55905

**Eleni Kousvelari, DDS, DSc**

Sandia National Laboratories, 1515 Eubank Boulevard, SE 5800,  
Albuquerque, NM 87185-1413

**Karl E. Krueger, PhD**

Program Director, Cancer Biomarkers Research Group, Division of Cancer  
Prevention, National Cancer Institute, 6130 Executive Plaza North, Suite  
3136, Rockville, MD 20852

**Joseph A. Loo, PhD**

Professor, UCLA, Department of Biochemistry, 402 Boyer Hall, Los Angeles, CA 90095

**Daniel Malamud, PhD**

Professor, New York University College of Dentistry, New York, NY 10010

**Irwin D. Mandel, DDS**

Cedar Grove, NJ

**Milton V. Marshall, PhD, DABT**

Baylor College of Medicine, Department of Radiology, Division of Molecular Imaging, One Baylor Plaza MS, BCM 360, Houston, TX 77030

**John T. McDevitt, PhD**

Professor, Department of Chemistry and Biochemistry, Center for Nano and Molecular Science and Technology, Texas Materials Institute, University of Texas at Austin, 1 University Station A5300 Austin, TX 78712

**Jiska Marianne Meijer, MD**

Department of Oral and Maxillofacial Surgery, University Medical Center Groningen, 9700 RB Groningen, the Netherlands

**James E. Melvin, DDS, PhD**

Director, Center for Oral Biology, Professor of Pharmacology and Physiology, Aab Institute for Biomedical Sciences, University of Rochester, Medical Center Box 611, 601 Elmwood Avenue, Rochester, NY 14642

**Fumi Mineshiba, DDS, PhD**

Gene Transfer Section, Gene Therapy and Therapeutics Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892

**Suhail K. Mithani, MD**

Johns Hopkins Medical Center, Baltimore, MD 21287

**Thiago Morelli, DDS**

Research Fellow, Michigan Center for Oral Health Research, University of Michigan Clinical Center, 24 Frank Lloyd Wright Dr, Lobby M, Box 422, Ann Arbor, MI 48106

**R. Sam Niedbala, PhD**

Lehigh University, 6 East Parker Avenue, Bethlehem, PA 18015

**Frank G. Oppenheim, DDS, PhD**

Professor and Chair, BU Goldman School Of Graduate Dentistry, W-201, Boston, MA 02118

**D. Stott Parker, PhD**

Professor, Department of Computer Science, University of California at Los Angeles, Box 951596, 3532H BH, Los Angeles, CA 90095

**Lance Presley, PhD, DABFT**

Quest Diagnostics, Lenexa, KS 66219

**Senrong Qi, DDS, PhD**

Gene Transfer Section, Gene Therapy and Therapeutics Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892

**Renli Qiao, MD, PhD**

Associate Professor of Clinical Medicine, Pulmonary and Critical Care Medicine, Keck School of Medicine, University of Southern California, 2011 Zonal Avenue, HMR911, Los Angeles, CA 90033

**Gabor Z. Racz, PhD**

Gene Transfer Section, Gene Therapy and Therapeutics Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892

**Christoph A. Ramseier, DMD**

School of Dental Medicine, Department of Periodontology, University of Berne, Freiburgstrasse 7, 3012 Bern, Switzerland

**Lindsay Rayburn, BS**

Research Specialist, Michigan Center for Oral Health Research, University of Michigan Clinical Center, 24 Frank Lloyd Wright Dr, Lobby M, Box 422, Ann Arbor, MI 48106

**Nelson L. Rhodus, DMD, MPH, FACD**

Professor and Director, Division of Oral Medicine, School of Dentistry, Adjunct Professor, Department of Otolaryngology, School of Medicine, Academy of Distinguished Teachers, Diplomate, American Board of Oral Medicine, University of Minnesota, 7536 Moos HST; 515 Delaware St SE, Minneapolis, MN 55455

**Victor G. Romanenko, PhD**

Research Assistant Professor, University of Rochester Medical Center, 601 Elmwood Avenue, Rochester, NY 14642

**Yuval Samuni, DMD, PhD**

Gene Transfer Section, Gene Therapy and Therapeutics Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892

**Jonathan A. Ship, DDS, PhD**

New York University College of Dentistry, Professor, Division of David B Kriser Dental Center, Department of Clinical Research Center, Weissman, 421 First Ave, 233 W, New York, NY 10010, NYU Mail Code: 9447

**Chakwan Siew, PhD**

American Dental Association, 211 East Chicago Avenue, Chicago, IL 60611

**Stuart R. Smith, BDS, PhD**

GlaxoSmithKline (GSK), Weybridge, Surrey, United Kingdom KT130DE

**Sudhir Srivastava, PhD, MPH, MS**

Program Director, EDRN, National Cancer Institute, 6130 Executive Boulevard, EPN 330F, Bethesda, MD 20892

**Takayuki Sugito, DDS, PhD**

Gene Transfer Section, Gene Therapy and Therapeutics Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892

**Lawrence A. Tabak, DDS, PhD**

Director, National Institute of Dental and Craniofacial Research, 30 Convent Drive, Bethesda, MD 20892

**Shawn Than, MS**

University of California at Los Angeles, School of Dentistry, 10833 Le Conte Avenue, 73-017 CHS, Los Angeles, CA 90095

**Michael D. Turner, DDS, MD**

Assistant Professor, New York University College of Dentistry, New York, NY 10010

**Enno C.I. Veerman, PhD**

Professor, Academic Centre for Dentistry Amsterdam (ACTA), van der Boechorststraat 7, 1081 BT Amsterdam, the Netherlands

**Arjan Vissink, DMD, MD, PhD**

Professor, Department of Oral and Maxillofacial Surgery, University Medical Center Groningen, Groningen, the Netherlands

**Antonis Voutetakis, MD, PhD**

Gene Transfer Section, Gene Therapy and Therapeutics Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892

**David R. Walt, PhD**

Robinson Professor of Chemistry, Tufts University, Department of Chemistry, 62 Talbot Avenue, Medford, MA 02155

**Andy Wolff, DMD**

Saliwell Ltd Medical Systems, Hatamar St, Harutzim 60917, Israel

**David T. Wong, DMD, DMSc**

University of California at Los Angeles, Professor and Associate Dean of Research, School of Dentistry, Director, Dental Research Institute, 10833 Le Conte Avenue, 73-017 CHS, Los Angeles, CA 90095

**Weihong Yan, PhD**

Keck Bioinformatics User Center, Department of Chemistry and Biochemistry, UCLA, 607 Charles E. Young Drive East, Los Angeles, CA 90095

**John R. Yates, PhD**

Professor, Scripps Research Institute, 10550, North Torrey Pines Rd, SR11, Department Cell Biology, La Jolla, CA 92037

**Weixia Yu, PhD**

University of California at Los Angeles, School of Dentistry, 10833 Le Conte Avenue, 73-017 CHS, Los Angeles, CA 90095

**Changyu Zheng, MD, PhD**

Gene Transfer Section, Gene Therapy and Therapeutics Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892

**Bernhard G. Zimmermann, PhD**

Assistant Researcher, Division of Oral Biology, UCLA School of Dentistry, Los Angeles, CA 90095

## Foreword

*“... there is no disease that I spit on more than treachery.”*  
Aeschylus (525-456 BC)

Saliva is one of those things you love or hate. Although historically scorned in literature, viewed by many cultures as the ultimate insult and clinically “damned,” investigators, clinicians, and our patients are increasingly turning to saliva as a safe and “non-invasive” indicator of health and disease. Many biomarkers may be measured using oral fluids. This opens up the extraordinary opportunity of enhancing research conducted in the field or expanding the versatility of point-of-care diagnostics by using saliva as the diagnostic fluid.

Behavioral research that seeks to correlate physiological with psychological status has been revolutionized by the availability of assays that accurately measure such hormones as cortisol in saliva. Reaction (and sometimes aversion) to a needle stick for collection of blood has a far greater chance of disturbing the subject than does the collection of oral fluid. Accurate and rapid diagnostic tests that can be performed in the privacy of one’s home or in a community or field setting are proving crucial to controlling a number of diseases and conditions. For example, such tests for sexually transmitted diseases can yield diagnosis in the early stages of the infection resulting in a decreased transmission from asymptomatic patients. Infectious diseases kill approximately 15 million persons worldwide each year. Saliva-based point-of-care diagnostic tests, which dispense with the need for a phlebotomist, have the potential to overcome some of the limitations and challenges of the modest medical infrastructures found in the developing world.

Continued advances in biomedical engineering coupled to enhance understanding of the salivary proteome will make it possible to one day implant biosensors directly in the mouth. These in-dwelling “labs on a chip” will help catalyze a shift from our current practice of disease detection to a health surveillance through detection and measurement of multiple, relevant biomarkers in saliva. With the advances of this technology comes the additional significant obligation to ensure the privacy of patients. While saliva collection is facile and anatomically non-invasive, oral fluids have sufficient quantities of DNA to decode genotypes. Thus, one must be equally discreet with saliva and blood samples.



The numerous contributors to this volume are experts in their respective areas and provide the historical background as well as the status of current research. They see salivary diagnosis developing into a new “industry;” they deal with its utilization in dentists’ and physicians’ offices and explore reimbursement mechanisms for the services. The projection into the future also considers testing at home and concerns regarding the commercial market.

*Salivary Diagnostics* provides insight into an area that will increasingly involve many disciplines.

Lawrence A. Tabak, DDS, PhD  
Irwin D. Mandel, DDS

# Preface

*This book is dedicated to the visionaries who planted and nurtured the seeds for saliva diagnostics to flourish and bear harvest.*

The publication of “Salivary Diagnostics” marks a defining moment. Revolutionary genome-wide research tools have spawned remarkable advances in human genomics, proteomics, and metabolomics. These interrelated developments, largely driven by the Human Genome Project, ushered a new dawn on the ancient study of saliva. We have learned that human saliva contains a repertoire of proteins, glycoproteins, lipids, metabolites, RNA and genomic information, in addition to the 700 microbial species and is endowed with many of the same diagnostic analytes inherent in other bodily fluids such as blood, cerebral spinal fluid, and urine.

The National Institute of Dental and Craniofacial Research charged into the inclement waters of risky science and planted its flag on the *terra incognita* of saliva omics. The completion of the human salivary proteome project is a landmark accomplishment marking the discovery of the first diagnostic alphabet in saliva. Now, the race is on for a self-contained diagnostic chip that can provide clinical information to a physician or dentist at point-of-care before a patient leaves the clinician’s office during a regular visit.

From the adventurer’s past, saliva diagnostics emerges into the clockmaker’s present. Now is the time for us to exchange adventurer’s leather jacket for a clockmaker’s loupe. We are in the critical phase where the scientific foundations of saliva for clinical disease detection must be established beyond any doubt. Only on the broadest foundation of absolute scientific integrity can we build the highest edifice of saliva diagnostics in the shortest possible time.

And the future? With the potential to revolutionize delivery of diagnostic services both on the personal and public health levels, the future of saliva diagnostics is enormous.

David T. Wong, DMD, DMSc

# Acknowledgment

I am thankful to Tanya Lazzar, the project manager; Carol Field, the task master; Shelby Hayes and Sophia Joyce at Wiley-Blackwell for their skills and professionalism in putting the book together.

To Alik Segal, who patiently assisted me in the editorial tasks of this book. And to my wife, Sharon, who supports me unconditionally.

# Part I

## **Background and Foundation**



# Salivary gland development and regeneration

Sarah M. Knox and Matthew P. Hoffman

## INTRODUCTION

The formation of salivary glands throughout embryogenesis is exquisitely orchestrated so that at birth the organ system is primed and ready to produce salivary secretions under the control of autonomic innervation. An appreciation for the developmental mechanisms that give rise to this complex and highly regulated system is an important foundation to understanding the physiology and biochemistry of postnatal saliva production, which is the fluid required for salivary diagnostics. In this chapter, we compare what is known about human salivary gland development with mouse submandibular gland development and highlight human genetic conditions that provide profound insight into gland development. We have also included a section on potential strategies for salivary gland regeneration.

## SALIVARY GLAND DEVELOPMENT

The salivary organ system is composed of three pairs of major glands: the submandibular (SMG), parotid, and sublingual (SLG), which together produce more than 90% of saliva, as well as numerous minor glands lining the oral cavity. The major salivary glands share homologous mechanisms of branching morphogenesis during organogenesis to produce an intricate branched structure of ducts with terminal buds that differentiate into acinar structures. They are also well supplied by the vascular system, which develops alongside, and is intimately associated with the branching epithelial structures. Little is known about vascular development in the salivary gland; salivary secretion is accompanied by increased blood flow to the glands, and an extensive capillary network is found around the striated duct where ion exchange occurs. The salivary glands are innervated by the parasympathetic and sympathetic branches of the autonomic nervous system, which are essential for postnatal saliva secretion and will be the focus of a section below. Human salivary glands are composed of different types of acinar cells that produce distinct types of saliva: parotid acinar cells are serous and secrete a watery serous saliva; SMG acinar cells are approximately 80% serous and also contain mucous secretory


units capped by seromucous demilunes, producing a seromucous saliva; SLG acinar cells are mixed secretory units but are mainly composed of mucous cells and produce a mucous saliva. The reader is directed to a textbook for a comprehensive histological description of cell types within the glands.<sup>1</sup>

The development of human and mouse salivary glands is similar in many aspects, and to highlight this point, we will compare human and mouse development in this chapter. There have been a few histological reports documenting human salivary gland development<sup>2–4</sup> that basically corroborate the early histological descriptions by Thoma in 1919, shown in Figure 1.1.<sup>5</sup> The parotid gland is derived from the oral ectoderm, and the mesenchyme is neural crest-derived ectomesenchyme. However, the origin of the SMG and SLG epithelium has not been clearly defined. Humans with mutations in the ectodysplasin A (*EDA*) gene develop hypohidrotic ectodermal dysplasia (HED), characterized by defects in teeth, hair, sweat glands, and salivary glands, and mice lacking the *EDA* receptor (*Edar*) have SMG aplasia or hypoplasia (recently reviewed in reference 6). Mice lacking p63, an ectodermal marker, have no salivary glands,<sup>7</sup> suggesting that the origins of the SMG and SLG are ectodermal.

Human salivary gland development begins with the thickening of the oral epithelium to form a placode at a specific site in the oral cavity. Figure 1.1 shows the parotid placode forming in the lateral border of the buccal sulcus of a human embryo. Factors that define the site of placode initiation of human and mouse salivary glands are not known. However, a recent review of salivary gland development in *Drosophila* describes how global patterning genes, such as the homeotic gene *scr*, define the site of salivary gland initiation, whereas other genes repress gland initiation in the anterior–posterior and dorsal–ventral axes.<sup>8</sup> Experimental evidence from *Drosophila* provides a paradigm for how gland initiation is likely to occur in humans and mice, and the reader is referred to Denny et al.<sup>9</sup> for discussion.


The next stage in development is the expansion and invagination of the placode as an epithelial bud into a condensing mesenchyme at around 6–8 weeks in humans (Fig. 1.2) and embryonic day 12 (E12) in mice.<sup>4,5</sup> The condensing mesenchyme provides growth factors and extracellular matrix that play an instructive role in branching morphogenesis of the mouse salivary gland (reviewed in references 6 and 10). The human SMG epithelium then undergoes successive rounds of branching morphogenesis, which involves cleft formation, end bud expansion, and duct elongation, finally appearing as solid end buds and cords of epithelial cells (Fig. 1.3) at 10 weeks,<sup>2,5</sup> similar to an E14 mouse SMG (Fig. 1.2). By 14 weeks, functional differentiation of the gland has started with branches and terminal buds forming lumens to establish presumptive ducts and acini.

Branching morphogenesis continues until approximately 12 weeks where lumenization of ducts and polarization of the end bud epithelium begins, similar to E15 in the mouse. However, from approximately 12 to 28 weeks, cellular differentiation begins with polarization of the end buds and lumenization of the ducts with secretory material appearing in the lumens of the ducts and end buds, similar to E17 in the mouse SMG (Fig. 1.2). Also, during mouse SMG development, the gene expression of secretory products, such as parotid secretory protein (PSP) and submandibular gland protein C (SMGc), is barely detectable



**Figure 1.1** (a) Early development of the human parotid gland. A section from an approximately 6–8-week-old human embryo shows the thickening of the parotid placode, which forms in the major groove of the buccal sulcus. (b) Development of the human SMG. At approximately 6–8 weeks, but later than that in part (a), the SMG rudiment extends into a condensed mesenchyme capsule that provides growth factors and matrix, which stimulate branching morphogenesis. (c) At 10 weeks, the SMG has undergone extensive branching within the mesenchymal capsule. The main duct is visible, and lumens can be seen in some minor ducts. (All figures from Reference 5.)





**Figure 1.2** Development of the mouse SMG. At E14, the branched epithelium consists of solid end buds and ducts. By E17, functional differentiation has begun with lumen formation and end bud polarization. At P1, the acinar cells are differentiated, but connective tissue remains around the parenchyma. By P5, the functioning acini have continued to enlarge, and ductal differentiation is apparent. Bar = 200  $\mu\text{m}$ .

by real-time polymerase chain reaction (PCR) at E15, but increase at E17 and after birth at postnatal day 1 (P1) (Fig. 1.3). By 13–16 weeks in human SMGs, cells adjacent to lumens show the presence of desmosomes and numerous microvilli projecting into the intercellular space. The cytoplasm of some cells contained serous, but not mucous, granules, and the luminal contents were strongly positive for glycosaminoglycans.<sup>11</sup> The epithelium is surrounded by a well-developed basal lamina and contains a few elongated cells that appear similar to myoepithelial cells. By 16 weeks, both striated ducts and intercalated ducts are distinguishable. From 20 to 24 weeks, acinar cells begin to predominate; in rodents (E18), granular convoluted tubules (GCTs) appear. By 28 weeks there is a marked increase in the amount of acini (and GCT cells in rodents),

**Figure 1.3** Differential gene expression of secretory products highlights the development of secretory function during mouse SMG development. FGF2 expression is increased during branching morphogenesis, whereas PSP and SMGc expression begins after E15 when functional differentiation begins. During postnatal development, EGF and NGF expression dramatically increases after puberty. Gene expression, normalized to the housekeeping gene 29S, was measured by real-time PCR, over a developmental time course from E12 to adult (Adt).



although less secretory products are apparent.<sup>2</sup> At birth, only serous cells are present, with connective tissue spaces between the acini, similar to P1 of mouse SMG development (Fig. 1.2). In humans, prenatal growth and differentiation continue after 28 weeks such that the glands are capable of secreting saliva in response to parasympathetic stimulation at P1. In comparison, postnatal mouse SMG development, particularly the differentiation of the GCTs by puberty, is evidenced by expression of GCT secretory gene products such as EGF, which is weakly expressed from E17 and at birth but dramatically increases after puberty, and NGF, which is barely detectable at P5 but also dramatically increases with postnatal ductal differentiation (Fig. 1.3).

## **DEVELOPMENT OF THE AUTONOMIC INNERVATION OF SALIVARY GLANDS**

Innervation of salivary glands by the parasympathetic and sympathetic branches of the autonomic nervous system is essential for secretion and tissue homeostasis because denervation results in loss of saliva production and atrophy of the tissue. For a comprehensive review of salivary gland innervation, the reader is directed to Proctor and Carpenter (2007).<sup>12</sup> Embryonic innervation of the human salivary glands has been described from histological sections,<sup>4</sup> but most experimental investigations have used rodent SMGs.

There are important differences between sympathetic and parasympathetic nerve development in salivary glands. First, sympathetic innervation is postnatal, around P3–P5. In contrast, parasympathetic innervation develops at the same time as the gland and requires an interaction with the salivary epithelium.<sup>13</sup> Second, the sympathetic efferent nerves, which release norepinephrine, arise from the superior cervical ganglion located away from the gland in the thoracic spinal cord. However, the parasympathetic nerves secrete acetylcholine and extend either from the otic ganglion, which innervates the parotid, or from the submandibular ganglion, which innervates both the SMG and SLG. The submandibular ganglion lies within the SMG, whereas the otic ganglion is separate from the parotid. Interestingly, branching morphogenesis of the parotid gland does not begin until otic neurons reach the initial epithelial bud. Most of what is known about embryonic development of the glandular parasympathetic ganglions is derived from early studies on mouse SMG development.<sup>14,15</sup>

## **HUMAN GENETIC CONDITIONS AFFECTING SALIVARY GLAND DEVELOPMENT**

There are a few human genetic conditions that affect salivary gland development leading to aplasia or hypoplasia. However, two of the most informative are due to mutations in genes that affect fibroblast growth factor (FGF) receptor signaling. Mutations in FGF10, resulting in haploinsufficiency, have been linked to aplasia of lacrimal and salivary glands (ALSGs) syndrome (OMIM

180920),<sup>16</sup> an autosomal dominant anomaly with aplasia or hypoplasia of the lacrimal and salivary systems. Importantly, mice also missing one copy of FGF10 or its receptor, FGFR2b, have severe salivary gland hypoplasia. Additionally, lacrimoauriculodentodigital (LADD) syndrome is an autosomal dominant disorder characterized by aplasia or hypoplasia of the lacrimal and salivary systems as well as abnormalities of the face, ears, eyes, mouth, teeth, digits, and genitourinary system. LADD syndrome occurs as a result of mutations in fibroblast growth factor receptors 2 and 3 (FGFR2, FGFR3), as well as in FGF10.<sup>17,18</sup> ALSG and LADD syndrome are thought to be allelic disorders with variable expressivity, possibly due to different types of FGF10 mutations.<sup>18</sup>


Other genetic diseases showing salivary gland phenotypes include mutations in EDA and its receptor, EDAR, which result in HED, characterized by abnormal ectodermal organs such as hair, teeth, sweat glands, and salivary glands. Similar phenotypes occur in *Tabby* (*Eda<sup>Ta</sup>*) and *Downless* (*Edar<sup>dl</sup>*) mutant mice.<sup>19</sup> *Eda<sup>Ta</sup>* SMGs are hypoplastic, while *Edar<sup>dl</sup>* SMGs are dysplastic. EDA/Edar signaling is essential for branching morphogenesis, lumen formation, and differentiation, but not for initial gland formation.<sup>20</sup>

## MODEL SYSTEMS TO STUDY SALIVARY GLAND DEVELOPMENT

As described earlier, there are many similarities in the development of the mouse SMG compared to human salivary glands, both in the histological development and also in the development of the secretory function of the gland. A major advantage of using mouse SMG to model human gland development is the ability to experimentally manipulate the mouse genome. Ex vivo mouse SMG organ culture allows the investigation of branching morphogenesis in a complex system that contains mesenchyme, epithelium, parasympathetic neurons, and endothelial cells forming the developing vasculature (Fig. 1.4). E12 SMGs, beginning with a single epithelial bud in a condensed mesenchyme, display reproducible branching morphogenesis in serum-free culture and appear similar to SMGs in vivo. SMG organ culture has been used extensively to explore the molecular mechanisms of epithelium–mesenchyme interactions, and a broad range of molecules have been identified that regulate epithelial branching, including constituents of the extracellular matrix, cell adhesion receptors, proteases, and growth factors. The reader is referred to recent detailed reviews on mouse SMG branching morphogenesis.<sup>6,10</sup>

## THE GOAL OF FUNCTIONAL SALIVARY GLAND REGENERATION

An irreversible loss of salivary gland function often occurs in humans after removal of salivary tumors, after therapeutic radiation of head and neck tumors, as a result of Sjögren's syndrome, and in certain rare genetic syndromes affecting FGF signaling. The loss of salivary gland function impairs the oral health of



**Figure 1.4** Ex vivo organ culture of E12 mouse SMGs for 48 h in serum-free media recapitulates the development of the gland in vivo. A single epithelial bud undergoes branching morphogenesis. The lower panel highlights the cellular complexity of the SMG. The epithelium (blue, laminin  $\alpha$ 1) is surrounded by nerves (green,  $\beta$ 3-tubulin) that extend from the parasympathetic submandibular ganglion at the base of the primary duct. The mesenchyme contains a large network of blood vessels (red, PECAM). The image is a projection of a confocal stack.

these patients and significantly affects their quality of life. Currently, patients are treated with parasympathetic mimetics such as pilocarpine, which rely on some gland function. Patients with some remaining salivary tissue could benefit from genetic reengineering to restore tissue function or from a regenerative approach to repair the gland. Patients with little or no functional gland tissue may need regenerative therapy or replacement with artificial salivary glands.<sup>21</sup>

Animal models used to investigate and develop techniques for functional regeneration of salivary glands include rodents, minipigs, and primates. Rat models have been used to investigate the effects of irradiation,<sup>22</sup> denervation, and ductal ligation,<sup>12</sup> and intraductal adenovirus injection for gene therapy.<sup>23</sup> Minipigs are a large animal model whose SMGs resemble the human gland and are useful for studying changes after gland irradiation<sup>24</sup> and for preclinical applications of gene transfer to salivary glands.<sup>25</sup>

## Genetic reengineering

Most research to date has focused on the reengineering and replacement of salivary glands. Reengineering of salivary glands is based on inductive gene transfer technology using recombinant viruses. A number of genes have been delivered successfully to nonhuman salivary glands in vivo, including human aquaporin 1 (*Aqp1*)<sup>26</sup> and aquaporin 5 (*Aqp5*).<sup>27</sup> Aquaporins are water channels located in acinar cells that facilitate the movement of water across the plasma bilayer. *Aqp1* has been shown to be acutely downregulated after radiation

therapy. Gene transfer of Aqp1 using adeno-associated virus into salivary glands partially transformed ductal cells into functional secretory cells in rats and minipigs.<sup>25,28</sup> Aqp1 gene therapy on irradiated human patients using adeno-associated virus is currently in clinical trials. This topic is elaborated in Chapter 27.

## Regenerate and repair

The use of stem cells to regenerate tissue is increasingly being utilized in many organ systems. Recently, Lombaert and coworkers<sup>29</sup> used GFP-labeled bone marrow stem cells (BMSCs) to regenerate irradiated mouse SMGs. They measured an increase in salivary secretion after mobilization of BMSCs in the irradiated tissue. However, the stem cells were not part of the epithelial compartment of the gland, but were exerting their effect from the mesenchyme.<sup>29</sup> Potentially, the effect may be mediated by repopulation of the vasculature or nerves to increase blood supply or innervation, as a reduction in either of these structures leads to gland atrophy.<sup>12</sup>

## Replace

Patients who have lost parenchyma because of disease, radiation therapy, or surgery are not candidates for gene transfer or regenerative/repair strategies, and total organ replacement is required. Organ replacement is hampered by the cellular complexity of the salivary gland and the necessity to regenerate functional secretory epithelium, nerves, blood vessels, and stromal tissue in an encapsulated organ space. Engineering of an “artificial” salivary gland may involve the use of synthetic or ECM-derived 3D scaffolds onto which cells are seeded to form a polarized secretory epithelium.<sup>26,30</sup>

In conclusion, understanding how salivary glands develop may facilitate gland regeneration and/or tissue-engineering approaches to restore secretory function in adult glands. Fundamental scientific knowledge provides a foundation for therapeutic interventions and will benefit from the translational and clinical utilities of saliva and its analytes, the thematic topic of this book.

## Acknowledgments

The authors thank Harry Grant, Vaishali Patel, and Ivan Rebutini for critical reading of the manuscript. This work was supported by the Intramural Research Program of the National Institute for Dental and Craniofacial Research at the National Institutes of Health.

## REFERENCES

1. Ten Cate AR. *Oral Histology: Development, Structure, and Function*, 5th edn. St. Louis: Mosby; 1998.
2. el-Mohandes EA, Botros KG, Bondok AA. Prenatal development of the human submandibular gland. *Acta Anat (Basel)* 1987;130(3):213–18.

3. Guizzetti B, Radlanski RJ. Development of the submandibular gland and its closer neighboring structures in human embryos and fetuses of 19–67 mm CRL. *Ann Anat* 1996;178(6):509–14.
4. Merida-Velasco JA, Sanchez-Montesinos I, Espin-Ferra J, Garcia-Garcia JD, Garcia-Gomez S, Roldan-Schilling V. Development of the human submandibular salivary gland. *J Dent Res* 1993;72(8):1227–32.
5. Thoma KH. A contribution to the knowledge of the development of the submaxillary and sublingual salivary glands in human embryos. *J Dent Res* 1919;1:95–143.
6. Tucker AS. Salivary gland development. *Semin Cell Dev Biol* 2007;18(2):237–44.
7. Yang A, Schweitzer R, Sun D, et al. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. *Nature* 1999;398(6729):714–18.
8. Kerman BE, Cheshire AM, Andrew DJ. From fate to function: the *Drosophila* trachea and salivary gland as models for tubulogenesis. *Differentiation* 2006;74(7):326–48.
9. Denny PC, Ball WD, Redman RS. Salivary glands: a paradigm for diversity of gland development. *Crit Rev Oral Biol Med* 1997;8(1):51–75.
10. Patel VN, Rebustini IT, Hoffman MP. Salivary gland branching morphogenesis. *Differentiation* 2006;74(7):349–64.
11. Gibson MH. The prenatal human submandibular gland: a histological, histochemical and ultrastructural study. *Anat Anz* 1983;153(1):91–105.
12. Proctor GB, Carpenter GH. Regulation of salivary gland function by autonomic nerves. *Auton Neurosci* 2007;133(1):3–18.
13. Coughlin MD. Target organ stimulation of parasympathetic nerve growth in the developing mouse submandibular gland. *Dev Biol* 1975;43(1):140–58.
14. Coughlin MD. Early development of parasympathetic nerves in the mouse submandibular gland. *Dev Biol* 1975;43(1):123–39.
15. Nishi R. Ability of developing epithelia to attract neurite outgrowth in culture is not correlated with the appearance of laminin. *J Neurosci Res* 1988;21(2–4):307–14.
16. Entesarian M, Matsson H, Klar J, et al. Mutations in the gene encoding fibroblast growth factor 10 are associated with aplasia of lacrimal and salivary glands. *Nat Genet* 2005;37:125–7.
17. Rohmann E, Brunner HG, Kayserili H, et al. Mutations in different components of FGF signaling in LADD syndrome. *Nat Genet* 2006;38(4):414–17.
18. Milunsky JM, Zhao G, Maher TA, Colby R, Everman DB. LADD syndrome is caused FGF10 mutations. *Clin Genet* 2006;69(4):349–54.
19. Thesleff I, Mikkola ML. Death receptor signaling giving life to ectodermal organs. *Sci STKE* 2002;2002(131):PE22.
20. Jaskoll T, Zhou YM, Trump G, Melnick M. Ectodysplasin receptor-mediated signaling is essential for embryonic submandibular salivary gland development. *Anat Rec A Discov Mol Cell Evol Biol* 2003;271(2):322–31.
21. Baum BJ. Prospects for re-engineering salivary glands. *Adv Dent Res* 2000;14:84–8.

22. Vissink A, s-Gravenmade EJ, Ligeon EE, Konings WT. A functional and chemical study of radiation effects on rat parotid and submandibular/sublingual glands. *Radiat Res* 1990;124(3):259–65.
23. Mastrangeli A, O'Connell B, Aladib W, Fox PC, Baum BJ, Crystal RG. Direct in vivo adenovirus-mediated gene transfer to salivary glands. *Am J Physiol* 1994;266(6, Pt 1):G1146–55.
24. Radfar L, Sirois DA. Structural and functional injury in minipig salivary glands following fractionated exposure to 70 Gy of ionizing radiation: an animal model for human radiation-induced salivary gland injury. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 2003;96(3):267–74.
25. Shan Z, Li J, Zheng C, et al. Increased fluid secretion after adenoviral-mediated transfer of the human aquaporin-1 cDNA to irradiated miniature pig parotid glands. *Mol Ther* 2005;11(3):444–51.
26. Tran SD, Sugito T, Dipasquale G, et al. Re-engineering primary epithelial cells from rhesus monkey parotid glands for use in developing an artificial salivary gland. *Tissue Eng* 2006;12(10):2939–48.
27. Delporte C, Baum BJ. Preclinical and biological studies using recombinant adenoviruses encoding aquaporins 1 and 5. *Eur J Morphol* 1998;36 (Suppl):118–22.
28. Zheng C, Hoque AT, Braddon VR, Baum BJ, O'Connell BC. Evaluation of salivary gland acinar and ductal cell-specific promoters in vivo with recombinant adenoviral vectors. *Hum Gene Ther* 2001;12(18):2215–23.
29. Lombaert IM, Wierenga PK, Kok T, Kampinga HH, deHaan G, Coppes RP. Mobilization of bone marrow stem cells by granulocyte colony-stimulating factor ameliorates radiation-induced damage to salivary glands. *Clin Cancer Res* 2006;12(6):1804–12.
30. Sun T, Zhu J, Yang X, Wang S. Growth of miniature pig parotid cells on biomaterials in vitro. *Arch Oral Biol* 2006;51(5):351–8.